Archimedis Laboratories Private Limited - Due diligence report

A 360° intelligence report on Archimedis Laboratories Private Limited: trust score, financial health, credit view, compliance, directors, gr…

2004-12-24 Hyderabad, Telangana Active Unlisted Active Compliant
Share
AL Archimedis Laboratories Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Archimedis Laboratories Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
80/100
Trust Score
Low Risk

Archimedis Laboratories Private Limited is assessed as Low Risk with a Trust Score of 80/100. Archimedis Laboratories Private Limited is an active private limited indian non-government company incorporated in 2004, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 20 Jul 2026 from the latest processed filings. Archimedis Laboratories Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
80/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
65/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
35/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
45/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 35/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 4 open (67.67 cr) · 6 satisfied (28.84 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Hdfc Bank Limited1 48.0 cr
Others3 48.0 cr
Andhra Bank3 48.0 cr
Axis Bank Limited1 48.0 cr
Andhra Bank Limited2 48.0 cr
Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 2 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
VENKATESWARA REDDY MADDIREDDY 01234567 Director 01/04/2018 6 yrs Approved
KESAVA REDDY MADDIREDDY 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 45 · Distress 55
Growth signals & trust indicators
Asset base grew 2.1x - capacity expansion.
Operating for 21+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Profit declined two years in a row.
Outside liabilities up 24% in a year.
4 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence76/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment57/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 4 open charge(s) of 67.67 cr already registered.
  • Compliance record supports lending.
Investor view61/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
26 Mar 2025
Charge created
Others - 3.50 cr
20 Mar 2025
Charge created
Others - 8.42 cr
07 Mar 2025
Charge satisfied
Axis Bank Limited
16 Jan 2025
Charge created
Others - 5.00 cr
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
27 Apr 2022
Charge created
Hdfc Bank Limited - 50.75 cr
31 Mar 2017
Securities allotted
647117 Equity Shares - 71.18 Lakh raised
27 Feb 2017
Charge satisfied
Andhra Bank
31 Jan 2017
Charge created
Axis Bank Limited - 12.79 cr
04 Sep 2015
Director ceased
KURAPATI KOTESWARA REDDY
30 Mar 2013
Securities allotted
1652792.00 Equity Shares - 1.65 cr raised
20 Feb 2013
Charge satisfied
Andhra Bank
31 Mar 2012
Securities allotted
1000000.00 Equity Shares - 1.00 cr raised
23 Nov 2010
Charge satisfied
Andhra Bank Limited
10

Key Observations

Auto-generated from the data above
Revenue declined 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Makcur Laboratories Limited U99999GJ1996PLC029439 Dehgam, Gujarat, India
Nuray Chemicals U24110TN2012PTC086320 Thiruvallur, Tamil Nadu, India
Hwatsi Chemical Private Limited U24100MH2003PTC142939 Mumbai, Maharashtra, India
Pregna U25209MH1993PLC073582 Mumbai, Maharashtra, India
Nikisu Fine Chemicals Private Limited U74900MH2010PTC200796 Mumbai, Maharashtra, India
Arbro Pharmaceuticals U24232DL1985PTC021362 Na, Delhi, India
Multichem Specialities Private Limited U24100MH2007PTC169587 Mumbai, Maharashtra, India
Meeraam Acids Private Limited U24116TZ1998PTC008514 Coimbatore, Tamil Nadu, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Archimedis Laboratories Private Limited before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Archimedis Laboratories Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 35/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 45/100, margin trends, ownership structure and peer set for Archimedis Laboratories Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 80/100, distress signals and MSME payment-delay disclosures - know whether Archimedis Laboratories Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Archimedis Laboratories Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Archimedis Laboratories Private Limited an active company?

Archimedis Laboratories Private Limited has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Archimedis Laboratories Private Limited financially healthy?

Archimedis Laboratories Private Limited has a Financial Health Score of 65/100 (Moderate) based on its filed financial statements.

Should I do business with Archimedis Laboratories Private Limited?

Its overall Trust Score is 80/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Archimedis Laboratories Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Archimedis Laboratories Private Limited have loans or charges against its assets?

4 open charge(s) are registered against its assets, and 6 earlier charge(s) stand satisfied.

Is Archimedis Laboratories Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Archimedis Laboratories Private Limited?

Its Credit Risk Score is 35/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.